Table 2: Laboratory findings in First Nations and Non-First Nations patients with nonalcoholic fatty liver disease.

Variable
(normal range)
First Nations
Baseline/follow-up
Non-First Nations
Baseline/follow-up
value
Baseline/follow-up

Duration of follow-up (yrs)2.9 ± 3.32.7 ± 3.10.731
ALT (<30 U/L)81 ± 52/59 ± 4183 ± 109/53 ± 430.92/0.49
AST (10–32 U/L)50 ± 31/43 ± 2458 ± 101/37 ± 220.66/0.13
ALP (30–120 U/L)151 ± 77/136 ± 72114 ± 61/102 ± 590.0002/0.004
GGT (5–38 U/L)119 ± 104/118 ± 119124 ± 177/110 ± 1910.88/0.82
Albumin (33–45 G/L)38 ± 3.9/38 ± 4.140 ± 6.1/40 ± 5.10.01/0.02
Total bilirubin (3–21 μmol/L)9.2 ± 6.4/8.5 ± 5.013 ± 32/12.3 ± 180.07/0.02
INR (0.9–1.1)1.0 ± 0.1/1.0 ± 0.11.4 ± 1.5/1.1 ± 0.60.72/0.57
Platelets (140–/L)279 ± 80/243 ± 83244 ± 71/239 ± 710.015/0.78
Creatinine (35–106 μmol/L)69 ± 21/70 ± 2277 ± 26/81 ± 460.164/0.07
Total cholesterol (<5.2 mmol/L)5.4 ± 0.96.9 ± 170.682
Triglycerides (<1.7 mmol/L)3.0 ± 2.25.2 ± 200.612
Glucose (3.6–6.0 mmol/L)8.2 ± 4.37.0 ± 7.50.006

Results represent mean ± SD.
ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma glutamyltransferase; INR: international normalization ratio.